Fiala

Peptide library › Digestive health

Glepaglutide

In clinical trialsDigestive health

Experimental long-acting GLP-2 medicine for short bowel syndrome, given once or twice a week.

What people use it for

What Glepaglutide does in the body

A GLP-2 analog that forms a slow-release store under the skin, helping the gut absorb more nutrients and fluid.

Strength of evidence

Moderate: a Phase 3 trial (EASE-1) reduced IV nutrition needs with twice-weekly dosing.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA.

How it's taken

Route: Injection under the skin, once or twice weekly (in trials)

How long it lasts (half-life): Long-acting

Keep track of Glepaglutide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Glepaglutide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Digestive health